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Combination chemotherapy based on bolus or infusional 5-ﬂuorouracil (5-FU), folinic acid (FA), together with either irinotecan
or oxaliplatin has become the standard of care for the ﬁrst-line treatment of metastatic colorectal cancer. The practice of combining
5-FU/FA with irinotecan or oxaliplatin is based on data from randomised clinical trials, and these are complicated by the variety of
endpoints used, including overall survival, progression-free survival and response rate. An evidence-based system has been devel-
oped by the United States National Cancer Institute, whereby oncology clinical trials are ranked according to the trial design and
the endpoints assessed. According to this system, the highest levels of evidence for the beneﬁt of ﬁrst-line combination therapy on
overall survival are achieved with the combination of irinotecan and bolus and/or infusional 5-FU/FA. Thus, if evidence-based
medicine is to be our aim, the combination of 5-FU/FA plus irinotecan should be the standard of care for the ﬁrst-line treatment of
metastatic colorectal cancer.
 2004 Elsevier Ltd. All rights reserved.
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For many years, clinicians have relied on 5-ﬂuoro-
uracil (5-FU) to treat their colorectal cancer patients [1].
Combining the drug with folinic acid (FA) enhanced its
cytotoxicity [2], and the combination of 5-FU/FA has
been the standard of treatment for advanced and met-
astatic colorectal cancer.
Over the years, a variety of regimens of 5-FU alone or
in combination with FA have been developed in an at-
tempt to optimise treatment. Commonly used regimens
include the bolus Mayo Clinic regimen [3], the bolus and
infusional de Gramont regimen [4], and the infusional
AIO (Arbeitzgemeinschaft Internische Onkologie) regi-
men (developed and popular in Germany) [5]. Although
infusional regimens of 5-FU/FA have improved re-
sponse rates and median progression-free survival
compared with bolus [2,4–6], and generally have im-
proved tolerability [6], overall survival beneﬁts have not* Tel.: +49-351-458-4781; fax: +49-351-458-5859.
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reproducible survival advantage of infusional regimens
and the convenience of bolus administration, bolus
regimens are still widely used in many centres and
countries, particularly in the United States.
In the late 1990s and early 2000s, data from a number
of key phase III randomised clinical trials conclusively
demonstrated that irinotecan improved survival as both
second- and ﬁrst-line therapy in patients with advanced
colorectal cancer compared with 5-FU/FA alone [7–9]
or (in the case of one trial in the second-line setting) best
supportive care [10]. In the last few years, another drug,
oxaliplatin, has also emerged as an eﬀective component
of 5-FU/FA-based regimens, with randomised studies
showing a signiﬁcant improvement in progression-free
survival compared with 5-FU/FA alone [11–13]. The
currently approved ﬁrst-line treatment for metastatic
colorectal cancer in Europe is infusional 5-FU/FA
combined with either irinotecan or oxaliplatin. In the
United States (US), irinotecan with bolus or infusional
5-FU/FA and oxaliplatin with infusional 5-FU/FA are
approved for use ﬁrst line.
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Fig. 1. Recording levels of evidence.
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The data available in the literature have been ob-
tained from clinical trials of varying design, such as
randomised and non-randomised, and using a variety of
end points, such as overall survival, progression-free
survival and response rate. The applicability of infor-
mation from clinical studies to clinical practice will de-
pend on a number of factors, including how robust the
study design is and how relevant the endpoints are to the
desired treatment goal.
An invaluable tool in the interpretation of clinical
trial data has been provided by the US National Cancer
Institute (NCI), which has developed a formal ranking
system of levels of evidence designed to assist physicians’
understanding and application of data from oncology
clinical trials [14]. Each trial has a two-tier ranking ac-
cording to both its design and its study endpoints (Table
1). In terms of trial design, the gold standard is the
double-blinded, randomised trial: this is assigned a
ranking of 1(i). However, in the ﬁeld of oncology, it is
frequently not possible to blind the physician to the
therapy delivered as there are often marked diﬀerences
in the therapeutic procedure or the side eﬀects of the
treatment: nonblinded trials are assigned a ranking of
1(ii), and this represents the highest level of evidence for
most oncology trials. For endpoints, the most important
one to patients is probably all-cause mortality (rankedTable 1
US National Cancer Institute levels of evidence for adult cancer treatment s
Strength of study design S
1(i) Double-blinded randomised
controlled clinical trial
Gold-standard study design.
Physician is blinded to treat-
ment allocation before and after
randomisation.
A
1(ii) Non-blinded randomised
controlled clinical trial
(allocation schema or
treatment delivery)
Assigned if blinding of the
therapy delivered cannot be
accomplished. This is often the
case with oncology trials, due to
the often marked diﬀerence in
procedures or adverse events of
treatments.
B
C
l
2. Non-randomised controlled
clinical trial
Trials in which treatment
allocation is known to the
investigator prior to obtaining
informed consent from the
patient.
D
D
D
D
3. Case series
3(i) Population-based
3(ii) Consecutive series
3(iii) Non-consecutive cases
These have the weakest form of
study design but may be the
only available or practical
information regarding a thera-
peutic strategy. These studies
do not have internal controls
Adapted from [14].A): this is also the easiest to deﬁne and the least subject
to investigator bias. Quality of life is also an important
endpoint for the patient (ranked C). Indirect surrogate
endpoints, such as progression-free survival, disease-free
survival and response rate may be useful in the absence
of other endpoints, but are all subject to investigator
interpretation and do not necessarily translate into a
direct patient beneﬁt, such as survival: these are given a
D ranking. Examples of recorded levels of evidence are
shown in Fig. 1.
In view of the choice of ﬁrst-line treatment ap-
proaches available for metastatic colorectal cancer in
Europe, it is appropriate to examine the clinical data for
the use of irinotecan- and oxaliplatin-based combina-
tions in terms of NCI levels of evidence.tudies
trength of endpoints
. Total mortality The most important endpoint
for patients, the most easily
deﬁned endpoint and the least
subject to investigator bias
. Cause-speciﬁc mortality
. Carefully assessed quality of
ife
Very important to patients
. Indirect surrogates
(i) Disease-free survival
(ii) Progression-free survival
(iii) Tumour response rate
All are subject to investigator
interpretation. Also, they do
not directly translate into
patient beneﬁt, such as survival
or quality of life
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3.1. Irinotecan as second-line therapy
Two independent randomised phase III trials showed
that the use of irinotecan second-line following disease
progression on 5-FU-based therapy signiﬁcantly im-
proved survival compared with bolus 5-FU/FA alone [7]
or best supportive care [10]. Survival was prolonged by
2.3 (P ¼ 0:035) and 2.7 (P ¼ 0:001) months, respectively.
Furthermore, the quality of life of the patients was either
signiﬁcantly improved [10] or unchanged [7]. For both
studies, the levels of evidence reached 1(ii) A for overall
survival and 1(ii) C for quality of life. These trials rep-
resent extremely high levels of evidence for the eﬃcacy of
an agent following failure on 5-FU-based therapy.
3.2. Irinotecan in ﬁrst-line therapy
Shortly after the second-line data were published, two
randomised phase III trials investigating combinations of
irinotecan and 5-FU/FA as ﬁrst-line treatment both
achieved the highest level of evidence (1(ii) A) for the
beneﬁt of irinotecan [8,9] (Table 2). In one trial, reported
by Saltz and colleagues, 683 patients were randomly as-
signed to receive either irinotecan (125 mg/m2) in com-
bination with 5-FU (500 mg/m2) and FA (20 mg/m2)
weekly for four weeks every six weeks (IFL, n ¼ 231); the
Mayo Clinic regimen of bolus 5-FU (500 mg/m2) and FA
(20 mg/m2), for ﬁve days every four weeks; or irinotecan
alone 125mg/m2 weekly for fourweeks every sixweeks [8].
An intention-to-treat analysis showed that the addition of
irinotecan to bolus 5-FU/FA led to a signiﬁcantly pro-
longed overall survival compared with bolus 5-FU/FA
alone (median 14.8 versus 12.6 months, P ¼ 0:04).
In the other trial, reported by Douillard et al. [9] 387
patients were randomised to receive either bolus and/or
infusional 5-FU/FA alone, according to the de Gramont
regimen (bi-weekly, LV5FU2) or the AIO regimen (onceTable 2
Levels of evidence for the eﬃcacy of adding irinotecan to bolus and/or infus
cancer
Regimen N Response rate
(%)
M
(
Bolus and infusional 5-FU/FA
(de Gramont) and infusional
5-FU/FA (AIO)
+ irinotecan [9]
385 22 4
35 6
Bolus 5-FU/FA
+ irinotecan [8]
457 21 4
39 7
Infusional 5-FU/FA (AIO)
+ irinotecan [15]
430 32a 6
54a 8
5-FU, 5-ﬂuorouracil; FA, folinic acid; AIO, Arbeitzgemeinschaft Internis
OS, overall survival; NS, not signiﬁcant.
aUnpublished information. See text for details of doses.weekly), or in combination with irinotecan. Treatment
regimens were as follows: irinotecan (80 mg/m2) plus 5-
FU (2300 mg/m2 by 24-h infusion) and FA (500 mg/m2),
once weekly (n ¼ 54); irinotecan (180 mg/m2) on day 1
plus 5-FU (400 mg/m2 bolus and 600 mg/m2 by 22-h
infusion) and FA (200 mg/m2) on days 1 and 2, bi-
weekly (n ¼ 145). For patients not receiving irinotecan,
the regimens were: 5-FU (2600 mg/m2 by 24-h infusion)
and FA (500 mg/m2), once weekly (n ¼ 43); or the de
Gramont regimen as described above (n ¼ 143). Overall
survival was signiﬁcantly longer in patients receiving
irinotecan compared with those receiving bolus and/or
infusional 5-FU/FA (median 17.4 versus 14.1 months,
P ¼ 0:031) (Table 2).
In another randomised trial (EORTC 40986), further
investigating the beneﬁt of adding irinotecan to the infu-
sional AIO regimen of 5-FU/FA, while the trial design
was robust, the level of evidence achieved was 1(ii) D(ii)
[15]. The trial was designed to administer irinotecan,
5-FU and FA according to the schedules used in the
Douillard study [9]. The addition of irinotecan signiﬁ-
cantly improved the response rate (54.2% versus 31.5%,
P < 0:0001) and the duration of progression-free survival
(8.8 versus 6.3 months, P < 0:0001). While overall sur-
vival in the irinotecan was in excess of 20 months, the
diﬀerence between the treatment arms did not attain sta-
tistical signiﬁcance (20.1 versus 16.9 months) (Table 2).
The lack of a signiﬁcant diﬀerence in overall survival may
be due to the fact that nearly two-thirds (62%) of patients
randomised to ﬁrst-line 5-FU/FA received second-line
therapy with irinotecan.4. Levels of evidence for oxaliplatin in metastatic
colorectal cancer trials
4.1. Oxaliplatin/5-FU/FA versus 5-FU/FA
The addition of oxaliplatin to various regimens of 5-
FU/FA was assessed in three randomised trials [11–13].ional 5-FU/FA regimens as ﬁrst-line therapy for metastatic colorectal
edian PFS
months)
Median OS
months
P value for
OS
Level of
evidence
1(ii) A
.4 14.1 0.031
.7 17.4
.4 12.6 0.04 1(ii) A
.0 14.8
.3 16.9 NS 1(ii) D(ii)
.8 20.1
che Onkologie; N, number of patients; PFS, progression-free survival;
Table 3
Levels of evidence for the eﬃcacy of adding oxaliplatin to bolus and/or infusional 5-FU/FA regimens as ﬁrst-line therapy for metastatic colorectal
cancer
Regimen N Response rate
(%)
Median PFS
(months)
Median OS
months
P value for
OS
Level of
evidence
Bolus and infusional 5-FU/
FA+oxaliplatin [11]
400 22 6.2 14.7 NS 1(ii) D(ii)
51 9.0 16.2
Chronomodulated 5-FU/FA
+oxaliplatin [13]
200 16 6.1 19.9 NS 1(ii) D(ii)
53 8.7 19.4
Bolus 5-FU/FA+oxaliplatin [12] 252 23 5.3 16.1 NS 1(ii) D(ii)
48 7.9 20.4
5-FU, 5-ﬂuorouracil; FA, folinic acid; N, number of patients; PFS, progression-free survival; OS, overall survival; NS, not signiﬁcant. See text for
details of doses.
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increase in survival and the level of evidence for the
eﬃcacy of oxaliplatin was only 1(ii) D(ii) for each trial
(Table 3).
In one of these trials, oxaliplatin (125 mg/m2 day 1)
was added to a 5-day course of chronomodulated 5-FU
(700 mg/m2 day) and FA (300 mg/m2/day) [13]. In an-
other, oxaliplatin (85 mg/m2 day 1) was combined with
LV5FU2 regimen of 2-h infusion of LV (200 mg/m2/
day) followed by a 5-FU (bolus 400 mg/m2/day and 22-h
infusion 600 mg/m2/day) for two consecutive days bi-
weekly [11]. In the third trial, oxaliplatin (50 mg/m2)
plus infusional 5-FU (2000 mg/m2 24-h infusion) and
FA (500 mg/m2), once a week for four weeks every ﬁve
weeks, was compared with the bolus Mayo Clinic regi-
men of 5-FU (425 mg/m2) and FA (20 mg/m2), days 1–5
every four weeks [12]. In all three trials, the addition of
oxaliplatin signiﬁcantly improved the response rate and
the progression-free survival. However, any diﬀerences
in overall survival did not reach statistical signiﬁcance.
4.2. Oxaliplatin/5-FU/FA versus irinotecan/5-FU/FA
Results from a randomised Intergroup trial (N9741)
directly comparing a number of diﬀerent treatment
regimens, including combinations of oxaliplatin/5-FU/
FA and irinotecan/5-FU/FA, were recently reported by
Goldberg et al. [16]. The trial demonstrated a statisti-
cally signiﬁcant prolongation of survival with the addi-
tion of oxaliplatin to infusional 5-FU/FA (FOLFOX4;
oxaliplatin 85 mg/m2, day 1, 5-FU 400 mg/m2 bolus and
600 mg/m2 22-h infusion, days 1 and 2, every two weeks)
compared with bolus IFL (irinotecan 125 mg/m2, bolus
5-FU 500 mg/m2 and FA 20 mg/m2, weekly for four
weeks every six weeks). In this study, FOLFOX4 was
associated with a signiﬁcantly higher response rate (45%
versus 31%, P ¼ 0:002), longer time to progression
(median 8.7 versus 6.9 months, P ¼ 0:0014) and a longer
overall survival (median 19.5 versus 15 months,
P ¼ 0:0001) compared with IFL. Accordingly, therefore,
this study achieved a level of evidence of 1(ii) A.However, there are a number of issues which may have
had a signiﬁcant impact on the survival outcome seen in
this trial. The ﬁrst is the use of two diﬀerent 5-FU/FA
regimens in the comparator arms. Infusional 5-FU/FA
regimens are associatedwith improved response rates and
median progression-free survival and better tolerability
than bolus regimens [2,4–6]. However, in Goldberg’s
study, only the oxaliplatin arm used an infusional 5-FU/
FA regimen; irinotecan was added to a bolus 5-FU/FA
regimen. A more valid comparison of oxaliplatin- and
irinotecan-based regimens requires the use of the same 5-
FU/FA schedule in each arm. Another issue concerns
salvage therapy at the time of disease progression: 67% of
IFL patients received salvage therapy, with only 24% re-
ceiving oxaliplatin, whereas 75% of FOLFOX4 patients
received therapy, with 60% receiving irinotecan. Thus,
more patients in the FOLFOX4 arm were exposed to
salvage therapy with an active agent to which advanced
disease had not previously been exposed. Finally, it
should be remembered that N9741 was not designed to
compare the eﬀects of the diﬀerent treatment arms on
survival. We need to turn to a phase III crossover trial,
reported by Tournigand et al. [17], to better understand
the impact of adding irinotecan or oxaliplatin to the same
5-FU/FA regimen. This trial investigated the sequential
use of irinotecan (180 mg/m2) plus the simpliﬁed bolus
and infusional LV5FU2 regimen (FOLFIRI) followed on
disease progression by oxaliplatin (100 mg/m2) in com-
bination with the same 5-FU/FA regimen (FOLFOX6)
compared with the reverse schedule (FOLFOX6/FOLF-
IRI) [17]. After two lines of chemotherapy, the median
second progression-free survival (the primary endpoint of
the study) was 14.2 months with FOLFIRI ﬁrst-line and
10.9monthswithFOLFOX6ﬁrst-line.First-line response
rates were 56% for FOLFIRI and 54% for FOLFOX6.
More patients with FOLFIRI (74%) were exposed to
second-line treatment with the other active agent than
with FOLFOX6 (62%) (oxaliplatin and irinotecan, re-
spectively). Although there was no signiﬁcant diﬀerence
in the median overall survival times between FOLFIRI/
FOLFOX6 and FOLFOX6/FOLFIRI (21.5 versus 20.6
C.-H. K€ohne / EJC Supplements Vol 2 No. 7 (2004) 3–7 7months, respectively), the schedule using FOLFIRI/
FOLFOX6 achieved the longest recorded survival in a
phase III trial.5. Conclusions
It is now generally accepted that patients with meta-
static colorectal cancer should be oﬀered ﬁrst-line che-
motherapy with a 5-FU/FA regimen in combination with
another active agent, such as irinotecan or oxaliplatin.
However, the data from clinical trials are confusing,
basing treatment beneﬁt on a variety of endpoints, such as
response rate, progression-free survival and overall sur-
vival. While tumour response rate and progression-free
survival may be useful surrogate endpoints, overall sur-
vival is the most reliable, unbiased indicator of outcome
and arguably the most important endpoint for patients.
Evidence-based analysis of the various trials of 5-FU/FA
in combination with irinotecan or oxaliplatin shows that
to date, only irinotecan/5-FU/FA has shown survival
beneﬁts compared with 5-FU/FA alone in trials designed
to assess this endpoint. Thus, if we agree that evidence-
based medicine is the desired approach, then 5-FU/FA
plus irinotecan should be the standard of care in the ﬁrst-
line chemotherapy of metastatic colorectal cancer.References
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